Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
MGMT
REST API REST API
Homo sapiens
MGMT is differentially expressed in 243 experiments: 82 organism parts: liver, brain, ... (80 more);, 156 disease states: normal, glioblastoma, ... (154 more);, 65 cell types 406 cell lines 32 compound treatments and 69 other conditions.
Orthologs Mgmt (Mus musculus)   Mgmt (Rattus norvegicus)   MGMT (Gallus gallus)   MGT1 (Saccharomyces cerevisiae)   MGMT (Danio rerio)   agt (Drosophila melanogaster)   mgmt (Xenopus laevis)   MGMT_CANFA (Canis familiaris)   (Compare orthologs)
Gene Ontology Term DNA methylation, DNA binding, methylated-DNA-[protein]-cysteine S-methyltransferase activity, DNA repair, response to toxin, DNA dealkylation involved in DNA repair, methyltransferase activity, nucleus, methylation, response to drug, transferase activity, nucleoplasm, response to DNA damage stimulus, response to ethanol, catalytic activity, calcium ion binding, cellular response to oxidative stress, DNA-methyltransferase activity, positive regulation of DNA repair, mammary gland epithelial cell differentiation, negative regulation of cell death, response to folic acid, DNA ligation, response to organic cyclic compound, cellular response to organic cyclic compound, cellular response to ionizing radiation, regulation of cysteine-type endopeptidase activity involved in apoptotic process
InterPro Term MethylG_MeTrfase, MethylDNA_cys_MeTrfase_DNA-bd
UniProt Accession P16455, Q6LDD1, B4DEE8
Search EB-eye ENSG00000170430
Show more properties
Experimental Factors
Organism part

studied in E-GEOD-803, E-GEOD-15765, E-AFMX-5, E-GEOD-6573, E-MEXP-1251, ... (23 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-17482, E-GEOD-5258, E-GEOD-19639, E-GEOD-18005, E-GEOD-2450, ... (41 experiments)

Factor Value U/D Experiments
MCF-7
4
E-GEOD-5823, E-GEOD-19639, E-GEOD-20081, E-GEOD-3529
MCF-10A
2
E-TABM-420, E-GEOD-14990
MDA-MB-231
2
E-TABM-420, E-MTAB-62
T84
2
E-GEOD-1474, E-MTAB-37
SW480
1
2
E-MEXP-1014, E-GEOD-2509, E-GEOD-18005
K562
1
2
E-MTAB-37, E-GEOD-24147, E-GEOD-96
400 more value(s).


Cell type

studied in E-GEOD-22529, E-TABM-40, E-GEOD-21668, E-MEXP-66, E-GEOD-20677, ... (33 experiments)

Factor Value U/D Experiments
stromal cell
2
E-GEOD-1460, E-MEXP-2034
endothelial cell
2
E-GEOD-19240, E-GEOD-3998
primary CD34- mesenchymal stem cell
1
E-MEXP-66
mature monocyte derived dendritic cell
1
E-GEOD-4984
CD8+ naive CD8 T cell
1
E-TABM-40
purified B cells from peripheral blood from donors 60 years of age and older
1
E-GEOD-22529
59 more value(s).


Disease state

studied in E-GEOD-3307, E-MTAB-62, E-GEOD-5418, E-GEOD-8607, E-GEOD-1145, ... (50 experiments)

Factor Value U/D Experiments
cervical carcinoma
3
E-MTAB-62, E-MEXP-1331, E-MTAB-37
prostate carcinoma
3
E-MTAB-62, E-MEXP-2034, E-GEOD-5377
lung carcinoma
2
E-GEOD-6014, E-MTAB-37
acute promyelocytic leukemia
2
E-GEOD-995, E-MTAB-62
glioblastoma
2
3
E-MTAB-37, E-MTAB-62, E-GEOD-4290, E-GEOD-6014, E-GEOD-4412 ... (5 experiments)
colorectal adenocarcinoma
1
2
E-MTAB-62, E-AFMX-5, E-MTAB-37
150 more value(s).


Compound treatment

studied in E-GEOD-6907, E-GEOD-15205, E-GEOD-3720, E-GEOD-5824, E-TABM-868, ... (20 experiments)

Factor Value U/D Experiments
lipopolysaccharide
2
E-MEXP-1958, E-TABM-868
interferon-gamma + lipopolysaccharide
1
E-GEOD-5099
vanadium pentoxide
1
E-GEOD-5339
MIG control
1
E-GEOD-15811
phoshate buffered saline
1
E-GEOD-3720
TNF
1
E-GEOD-15205
26 more value(s).


Agent

studied in E-GEOD-19519

Factor Value U/D Experiments
thapsigargin
1
E-GEOD-19519
tunicamycin
1
E-GEOD-19519


BioSourceProvider
studied in E-GEOD-19519, E-GEOD-19480

Blood/non-blood meta-groups
studied in E-MTAB-62

Bmngrd
studied in E-GEOD-20194, E-GEOD-16716

Cell treatment
studied in E-MEXP-1192

Cellular component
studied in E-GEOD-1400

Clinical history
studied in E-GEOD-19743, E-GEOD-7967, E-GEOD-21589, E-GEOD-16363, E-GEOD-1725, ... (6 experiments)

Clinical info
studied in E-GEOD-19743, E-MTAB-37, E-MEXP-1251, E-GEOD-2034, E-GEOD-1563, ... (8 experiments)

Clinical treatment
studied in E-GEOD-6532, E-GEOD-21610

coriell cell line repository identifier
studied in E-GEOD-19519

Developmental stage
studied in E-MEXP-2359, E-GEOD-2666, E-GEOD-4667, E-MEXP-2283, E-MTAB-62 ... (5 experiments)

Disease stage
studied in E-GEOD-7463

Disease staging
studied in E-GEOD-89, E-GEOD-1323, E-GEOD-19743, E-GEOD-7788, E-GEOD-3325, ... (8 experiments)

Environmental stress
studied in E-GEOD-1643, E-GEOD-1518, E-GEOD-3720

Er
studied in E-GEOD-20194, E-GEOD-16716

Er ihc
studied in E-GEOD-21653

Estrogen receptor status
studied in E-GEOD-6532, E-GEOD-20194, E-GEOD-16716

Ethnic group
studied in E-GEOD-1643, E-GEOD-20194, E-GEOD-16716

family id
studied in E-GEOD-19519

Family relationship
studied in E-MEXP-1425

Genetic modification
studied in E-MEXP-1482, E-MEXP-563

Genotype
studied in E-MEXP-149, E-GEOD-17476, E-GEOD-2292, E-TABM-868, E-TABM-601, ... (7 experiments)

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-TABM-263, E-MEXP-1220, E-GEOD-20540, E-MEXP-1446, E-GEOD-22278, ... (7 experiments)

Her2 ihc
studied in E-GEOD-20194, E-GEOD-16716

Histology
studied in E-TABM-276

Individual
studied in E-TABM-325, E-MTAB-197, E-TABM-740, E-MEXP-2069, E-GEOD-1926, ... (34 experiments)

Infection
studied in E-GEOD-12108, E-GEOD-980

Injury
studied in E-GEOD-19743

Irradiate
studied in E-GEOD-1977

Karyotype
studied in E-GEOD-22056

Ki67 ihc
studied in E-GEOD-21653

Labeling
studied in E-LGCL-5

Light
studied in E-GEOD-1725

Material type
studied in E-MEXP-455

Media
studied in E-MEXP-765

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Molecular subtype
studied in E-GEOD-21653

organ
studied in E-GEOD-24283

Organism
studied in E-GEOD-7540, E-GEOD-1801, E-AFMX-1

Organism status
studied in E-GEOD-19188

Performer
studied in E-LGCL-5

Phase
studied in E-GEOD-4888

Phenotype
studied in E-GEOD-22309, E-GEOD-21750, E-GEOD-6434, E-GEOD-17636, E-GEOD-7114 ... (5 experiments)

Population
studied in E-GEOD-4922

Progesterone receptor status
studied in E-GEOD-20194, E-GEOD-16716

Protocol type
studied in E-GEOD-22097, E-GEOD-3254, E-GEOD-21837, E-GEOD-19445, E-GEOD-19246, ... (6 experiments)

Qpcr egfr dct
studied in E-GEOD-5851

Rna integrity
studied in E-TABM-325

RNAi
studied in E-GEOD-12438, E-GEOD-1676, E-GEOD-3697, E-MEXP-1857, E-MEXP-2759 ... (5 experiments)

Sample preparation
studied in E-GEOD-16728

sampleID
studied in E-GEOD-24283

Sampling time point
studied in E-GEOD-16797, E-GEOD-19743, E-GEOD-17400

sbr grade
studied in E-GEOD-21653

Sex
studied in E-GEOD-7540, E-GEOD-7307

Sirna
studied in E-GEOD-21574

Strain or line
studied in E-MEXP-1996

Subtype
studied in E-GEOD-24283

Survival time
studied in E-GEOD-19188

Test result
studied in E-TABM-276

Treatment
studied in E-GEOD-21909, E-GEOD-19246, E-GEOD-13818, E-GEOD-19815, E-GEOD-12198 ... (5 experiments)

Treatment code
studied in E-GEOD-20194, E-GEOD-16716

Treatments comments
studied in E-GEOD-20194, E-GEOD-16716

Tumor grading
studied in E-TABM-147

Vehicle
studied in E-GEOD-5258

Processing time: 0.436 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM